Drug Trial Radar · NCT06006585
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
Last checked: Nov 20, 2026Latest source record: Feb 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Oct 6, 2023
Primary completion
May 24, 2024
Study completion May 24, 2024
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Aug 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with geographic atrophy, an advanced form of age-related macular degeneration. People can join the study if they are at least 50 years old. The purpose of this study is to find out how well different doses of a medicine called BI 771716 are tolerated. This study has 2 parts. Part 1 of the study takes about 3 months. In this part, participants receive 1 injection of BI 771716 directly into one of the eyes affected by geographic atrophy. Part 2 of the study takes about 4 months. In this part, participants receive 2 injections of BI 771716 directly into the eye. There are 4 weeks between the first and the second injection. In this study, BI 771716 is given to humans for the first time. The doctors compare how well participants tolerate the different doses of BI 771716. The doctors also regularly check the general health of the participants.
Conditions
- Geographic Atrophy
Interventions
BI 771716Drug
BI 771716
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of ocular dose limiting events (DLEs) from drug administration until Day 8Time frame: Up to 7 days
- Occurrence of drug-related adverse events (AEs) from drug administration until end of study (EOS)Time frame: Up to 112 days
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Bay Area Retina Associates - Walnut Creek
Walnut Creek, California
Florida Retina Institute
Jacksonville, Florida
Florida Eye Associates
Melbourne, Florida
Verum Research, LLC
Eugene, Oregon
Erie Retina Research, LLC
Erie, Pennsylvania
Tennessee Retina
Nashville, Tennessee
Austin Clinical Research, LLC
Austin, Texas
Retina Consultants of Houston, PA-Houston-62050
Houston, Texas
Retina Consultants of Texas-The Woodlands-67575
The Woodlands, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.